Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod-Reference-Cited by-同舟云学术

Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

Published:2023-11-09 Issue: Volume: Page:
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

van Kempen Zoé LE¹^ORCID,van Dam Koos PJ²,Keijser Jim BD³^ORCID,Stalman Eileen W²,Kummer Laura YL²³,Strijbis Eva MM¹^ORCID,Steenhuis Maurice³⁴,ten Brinke Anja³,van Ham S. Marieke³⁵,Kuijpers Taco⁶,Rispens Theo³^ORCID,Eftimov Filip²,Wieske Luuk²⁷,Killestein Joep¹

Affiliation:

1. Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands

2. Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands

3. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands

4. Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, The Netherlands

5. Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands

6. Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands

7. Department of Clinical Neurophysiology, St. Antonius Hospital, Nieuwegein, The Netherlands

Abstract

Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear. Methods: Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination. Results: Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant. Conclusion: Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients.

Funder

ZonMw

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585231207761

Reference6 articles.

1. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

2. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod

3. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis

4. Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors

5. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19